Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Up – Here’s Why

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) gapped up prior to trading on Friday . The stock had previously closed at $19.20, but opened at $20.19. Damora Therapeutics, Inc. Common Stock shares last traded at $18.22, with a volume of 197,598 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DMRA shares. Lifesci Capital raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Wall Street Zen raised Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research report on Friday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Finally, UBS Group started coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.67.

Damora Therapeutics, Inc. Common Stock Stock Down 5.5%

The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -1.50 and a beta of 1.42. The stock’s fifty day moving average is $26.93 and its 200-day moving average is $19.01.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of large investors have recently made changes to their positions in DMRA. Virtu Financial LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the third quarter worth about $49,000. Geode Capital Management LLC acquired a new position in Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $266,000. Ikarian Capital LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $6,574,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,774,000. Finally, Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $2,772,000. Institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.